CN101804030B - Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof - Google Patents
Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof Download PDFInfo
- Publication number
- CN101804030B CN101804030B CN200910095834A CN200910095834A CN101804030B CN 101804030 B CN101804030 B CN 101804030B CN 200910095834 A CN200910095834 A CN 200910095834A CN 200910095834 A CN200910095834 A CN 200910095834A CN 101804030 B CN101804030 B CN 101804030B
- Authority
- CN
- China
- Prior art keywords
- micro
- micropill
- sodium
- pill
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to the pharmaceutical preparation field and in particular to a sodium dichlorophenolate micro-pill pharmaceutical preparation and a preparation method thereof. The micro-pill pharmaceutical preparation is prepared by micro-pills, which is characterized in that the micro-pill is of enteric slow-release micro-pill, the micro-pill consists of a hollow pill core, an active layer and an outer layer lagging cover, the active layer comprises sodium dichlorophenolate, a binding-property slow-release material and a binding-property enteric material, and the outer layer comprises a slow-release material. With the particular process and formula, a release system thereof is made into a unique double slow-release system, i.e. a skeleton-type scattering system is combined with a multi-layer semi-penetration film lagging cover system, so the main medicine can be continuously and stably released in the complicated internal environment of the human body. In addition, by adopting unique auxiliary materials, the micro-pill is free from being dissolved in the stomach and almost has no harm on the gastric mucosa, the medicine is ensured to have continuous effect of 24 hours inside the intestinal tract, the bioavailability is improved, and the application effect of the medicine is ensured.
Description
Technical field
The present invention relates to field of medicine preparations, relate in particular to a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof.
Background technology
Diclofenac sodium (diclofenac) is the antiinflammatory of fenamic acids micropill non-steroidal, the analgesic of being developed in sixties Mo by Switzerland vapour Ba-Jia Ji company (Ciba-Geigy).The COX (epoxidase) that these article produce because of inflammatory reaction through the inhibition tissue, thus the synthetic of prostaglandin reduced.Local prostaglandin is synthetic to be reduced, and has alleviated pain perception, plays the effect of periphery property analgesic.Since patent in 1998 expires, gone on the market successively in Germany, France, Britain, Japan, Italy, the U.S. etc.Existing more than 120 countries of China that comprise in the whole world sell and clinical use at present; Since 1974, the production and sales volume increases rapidly year by year, and since 1998; The sales volume of diclofenac sodium occupies the ntipyretic analgesic medicine first place, and leading more than other antipyretic analgesic.Tablet, slow releasing pill, slow releasing tablet, slow release suppository, antiinflammatory have mainly been developed in the market with collyrium and eye drop, injection lyophilized preparation, granule, slow releasing capsule etc.Domestic gel, paster, aerosol, suppository, enteric coatel tablets, slow releasing tablet, eye drop, slow releasing capsule in addition.Though the preparation of enteric and slow release is arranged, does not all combine both.The oral back of tablet is long in the time that stomach stops, and is bigger to gastric mucosa injury.Though the slow releasing capsule dosage form has reduced the zest to stomach, he is unfavorable for lasting release, the absorption of medicine under the alkaline environment of small intestinal, causes curative effect lasting time very short.Existing technology can not fine solution to gastrointestinal untoward reaction problem and guarantee the 24h continuous and effective.
Summary of the invention
The object of the present invention is to provide a kind of GI irritation property little, the sodium dichlorophenolate micro-pill pharmaceutical preparation of bioavailability height and good patient compliance.
Another object of the present invention is to provide a kind of method for preparing of sodium dichlorophenolate micro-pill pharmaceutical preparation.
The present invention is increased to the adhesive slow-release material to contain in 2/3 the diclofenac sodium; Can obtain to receive the release layer of double-layer sustained release film control; Reuse adhesive enteric material and remaining 1/3 diclofenac sodium continue to be increased to that to obtain PH in the above-mentioned micropill dependent at the undissolved active layer of gastric, and then at active layer outerwrap slow-release material.
In order to solve the problem that exists in the background technology, the present invention adopts following technical scheme:
A kind of sodium dichlorophenolate micro-pill pharmaceutical preparation; Described pellet preparations is to be prepared into various dosage forms by micropill; Described micropill is an enteric sustained-release pellet; This micropill is made up of celphere, active layer and outer coating, and described active layer comprises diclofenac sodium, cohesive slow-release material and cohesive enteric material, and skin comprises slow-release material.
Described celphere is one or more mixing in sucrose ball core, microcrystalline Cellulose ball core, the starch ball core.
Described cohesive slow-release material be gather first ammonium acrylate ester I, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, Ammonio Methacrylate Copolymer TypeA, Ammonio Methacrylate Copolymer Type B, gather first ammonium acrylate ester II, polyvinylpyrrolidone, in one or more mixing.
Described cohesive enteric material is one or more mixing in polyacrylic resin II, polyacrylic resin III, Methacrylic Acid Copolymer Type A, Methacrylic Acid Copolymer Type B, the Lac.
Described outer coating contains plasticizer, and described plasticizer is one or more mixing in triethyl citrate, diethyl phthalate, certain herbaceous plants with big flowers two dibutyl phthalates.
Described pellet preparations can be prepared into capsule, tablet or granule.
Described micropill comprises following weight percentage ratio component: diclofenac sodium 30%～60%, celphere 30%～60%, adhesive slow-release material 1%～10%, adhesive enteric material 0.1%～5%.
The optimization formula diclofenac sodium 510g of preparation 1000g micropill, celphere (starch) 400g, Ammonio Methacrylate Copolymer Type A 60g, Lac 10g, diethyl phthalate 2g, Pulvis Talci 10g.
The invention also discloses a kind of method for preparing of sodium dichlorophenolate micro-pill pharmaceutical preparation, described method for preparing comprises:
1) celphere is put in the coating pan, and regulated the coating pan temperature;
2) regulating the coating pan rotating speed is 10～60 rev/mins, sprays to contain 12% slow release binder solution, makes celphere moistening, spills the principal agent diclofenac sodium in right amount with spoon then, and ventilation simultaneously makes microgranule dry; Spray adhesive property slow-release material solution makes it moistening again, repeats said process, adds the diclofenac sodium of prescription total amount 2/3, drying;
3) sieve and obtain micropill of the same size, and collect the principal agent fine powder;
4) micropill is put in the coating pan again, the coating pan rotating speed is 10～60 rev/mins, drying;
5) the adhesive enteric material solution of configuration 10%, regulating the coating pan rotating speed is 10～60 rev/mins, spray adhesive property enteric material solution, and then spill an amount of principal agent diclofenac sodium (remaining the principal agent that 1/3 diclofenac sodium and screen cloth top sieve fall).Micropill is dry, repeats said process to adding all principal agents;
6) sieve and obtain micropill of the same size, and collect the principal agent fine powder;
7) micropill is placed in the coating pan again 10～60 rev/mins of coating pan rotating speeds, drying;
8) regulate the coating pan rotating speed: 10～60 rev/mins, spray coating solution, and spill the principal agent fine powder that step 6) is collected, the repetition said process is put and is used up coating solution; The dry micropill that gets.
Described micropill is prepared into the diclofenac sodium enteric-soluble controlled-release capsule.
Described micropill is added additive of tablet be prepared into diclofenac sodium enteric slow release tablet.
Described micropill is prepared into granule.
From technology of the present invention; Whole process will experience drying 3 times, and principal agent and the adding several times of adjuvant branch, but each layer of micropill is not the simple mixing of principal agent and adjuvant in process of production; But alternately spray layer by layer each other; Until principal agent that adds ormal weight and adjuvant, and strict control production temperature and operating time, the consistent micropill of homogeneous finally obtained.Because distinctive technology of the present invention and prescription; Make its release mechanism become a kind of dual-sustained-release system of uniqueness; Promptly,, make principal agent can in the interior environment of human body complicacy, continue, stably discharge in conjunction with multilamellar semipermeable membrane coating system through skeleton disperse system.In addition, owing to adopted unique adjuvant, make micropill of the present invention not dissolve at gastric, almost harmless to gastric mucosa, and guaranteed that medicine brings into play the continuous and effective of 24h in intestinal.Improve bioavailability, guarantee the result of use of medicine.
The specific embodiment
Below in conjunction with embodiment the present invention is further specified.
Embodiment 1: present embodiment prepares 1000g diclofenac sodium enteric sustained-release pellet and adopts following prescription:
Diclofenac sodium 510g, celphere (starch) 400g, Ammonio Methacrylate Copolymer Type A 60g, Lac 10g, diethyl phthalate 2g, Pulvis Talci 10g.
Preparation technology:
Load principal agent: starch ball core is placed in the coating pan, and regulate the coating pan temperature and put 25 ± 5 ℃.Alcoholic solution with 95% ethanol preparing A mmonio Methacrylate Copolymer Type A; The concentration of Ammonio Methacrylate Copolymer Type A alcoholic solution is 12%, and regulating the coating pan rotating speed is 30 rev/mins, sprays Ammonio Methacrylate Copolymer Type A alcoholic solution with spray gun; Discharge rate is per second 10～15g; Make starch ball core moistening, spill the principal agent diclofenac sodium in right amount with spoon then, and ventilation simultaneously makes microgranule dry; Crossing mesh is the double-deck screen cloth of 990 μ m/1180 μ m, obtains microgranule of the same size and collects the principal agent fine powder; Repeat said process then, until the diclofenac sodium of the 2/3 about 340g that adds the diclofenac sodium total amount; With 95% ethanol preparation Lac alcoholic solution, configuration concentration is 10%, and regulating the coating pan rotating speed is 30 rev/mins; Temperature is 18 ℃～23 ℃, and with spray gun spray Lac alcoholic solution, discharge rate is per second 10g～15g; Spill principal agent diclofenac sodium (the diclofenac sodium fine powder that remaining 170g diclofenac sodium and mesh screen fall) then, micropill is dry, repeats this process until adding all principal agents; Crossing mesh is the double-deck screen cloth of 990 μ m/1180 μ m, obtains microgranule of the same size and collects the principal agent fine powder.
Coating: regulating the coating pan rotating speed again is 30 rev/mins; Temperature still is 18 ℃～23 ℃, sprays Ammonio Methacrylate Copolymer Type A alcoholic solution with spray gun, and spills the principal agent fine powder of collection in right amount with spoon; Repeat this process; Spill diethyl phthalate and Pulvis Talci in right amount with spoon after adding all principal agents, repeat this process, until using up all Ammonio Methacrylate Copolymer Type A alcoholic solution.Drying is 6 hours under 40 ℃ of conditions.
The micropill cover capsule shells that obtains is got the diclofenac sodium enteric-soluble controlled-release capsule.
The diclofenac sodium enteric-soluble controlled-release capsule that present embodiment obtains can continue at intestinal within a certain period of time, the certain density diclofenac sodium of stable release; Thereby can reduce zest greatly in that the gastric dissolubility is very little to stomach; Improve bioavailability, guarantee the result of use of medicine.
The stripping of the micropill principal agent that present embodiment obtains is after dissolving in small intestinal because of the coatings of micropill; 1/3 principal agent dissolves the entering intestinal gradually, in addition because the difference of the inside and outside osmotic pressure of micropill, make that body fluid gets into micropill after; As producing inside and outside osmotic pressure after the starch particle dissolution of core; The principal agent composition is disengaged gradually, because Lac and polyacrylic resin have certain retardation to principal agent, make principal agent slowly stably to discharge again.
Technology from present embodiment; Whole process will experience drying 3 times, and principal agent and the adding several times of adjuvant branch, but each layer of micropill is not the simple mixing of principal agent and adjuvant in process of production; But alternately spray layer by layer each other; Until principal agent that adds ormal weight and adjuvant, and strict control production temperature and operating time, the final micropill that obtains unanimity.Because distinctive technology of the present invention and prescription; Make its release mechanism become a kind of dual-sustained-release system of uniqueness; Promptly,, make principal agent can in the interior environment of human body complicacy, continue, stably discharge in conjunction with multilamellar semipermeable membrane coating system through skeleton disperse system.In addition, owing to adopted unique adjuvant, make the present embodiment micropill not dissolve at gastric, almost harmless to gastric mucosa, and guaranteed that medicine brings into play the continuous and effective of 24h in intestinal.Improve bioavailability, guarantee the result of use of medicine.
Embodiment 2: present embodiment provides the agent of a kind of sodium dichlorophenolate micro-pill pharmaceutical matrix, is made by the sodium dichlorophenolate micro-pill pharmaceutical tabletting.
The preparation of micropill is identical with embodiment 1, and adds 10% (w/w) disintegrating agent, 0.5% magnesium stearate lubricant; Disintegrating agent can be selected carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose etc., preferred carboxymethyl starch sodium.Adopting intelligent tablet machine to carry out tabletting obtains.
Embodiment 3: present embodiment prepares 1000g diclofenac sodium enteric sustained-release pellet and adopts following prescription:
Diclofenac sodium 310g sucrose celphere 600g gathers first ammonium acrylate ester II50g
Methacrylic Acid Copolymer Type A 10g triethyl citrate 2g Pulvis Talci 10g
Preparation technology is identical with embodiment 1.The micropill that obtains is prepared into granule.
Embodiment 4: present embodiment prepares 1000g diclofenac sodium enteric sustained-release pellet and adopts following prescription:
Diclofenac sodium 600g sucrose celphere 3100g polyvinylpyrrolidone 55g
Lac 8g triethyl citrate 2g Pulvis Talci 10g
Preparation technology is identical with embodiment 1.The micropill cover capsule that obtains is obtained.
Embodiment 5: present embodiment prepares 1000g diclofenac sodium enteric sustained-release pellet and adopts following prescription:
Diclofenac sodium 350g starch celphere 580g gathers first ammonium acrylate ester 55g
Lac 8g triethyl citrate 2g Pulvis Talci 12g
Preparation technology is identical with embodiment 1.
Claims (8)
1. sodium dichlorophenolate micro-pill pharmaceutical preparation; Described pellet preparations is to be prepared into various dosage forms by micropill; It is characterized in that described micropill is an enteric sustained-release pellet; This micropill is made up of celphere, active layer and outer coating, and described active layer comprises diclofenac sodium, cohesive slow-release material and cohesive enteric material, and skin comprises slow-release material; Described micropill comprises following weight percentage ratio component: diclofenac sodium 30%～60%, celphere 30%～60%, adhesive slow-release material 1%～10%, adhesive enteric material 0.1%～5%; Described sodium dichlorophenolate micro-pill pharmaceutical preparation employing is prepared as follows method and obtains:
1) celphere is put in the coating pan, and regulated the coating pan temperature;
2) regulating the coating pan rotating speed is 10～60 rev/mins, sprays to contain 12% slow release binder solution, makes celphere moistening, spills the principal agent diclofenac sodium in right amount with spoon then, and ventilation simultaneously makes microgranule dry; Spray adhesive property slow-release material solution makes it moistening again, repeats said process, adds the diclofenac sodium of prescription total amount 2/3, drying;
3) sieve and obtain micropill of the same size, and collect the principal agent fine powder;
4) micropill is put in the coating pan again, the coating pan rotating speed is 10～60 rev/mins, drying;
5) configuration 10% adhesive enteric material solution, regulating the coating pan rotating speed is 10～60 rev/mins, spray adhesive property enteric material solution, and then spill the principal agent that residue 1/3 diclofenac sodium and screen cloth top sieve fall; Micropill is dry, repeats said process to adding all principal agents;
6) sieve and obtain micropill of the same size, and collect the principal agent fine powder;
7) micropill is placed in the coating pan again 10～60 rev/mins of coating pan rotating speeds, drying;
8) regulate the coating pan rotating speed: 10～60 rev/mins, spray coating solution, and spill the principal agent fine powder that step 6) is collected, repeat said process to using up coating solution; The dry micropill that gets;
9) the gained micropill is prepared into various preparations.
2. a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation according to claim 1 is characterized in that described celphere is one or more mixing in sucrose ball core, microcrystalline Cellulose ball core, the starch ball core.
3. a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation according to claim 1 is characterized in that described cohesive slow-release material is to gather first ammonium acrylate ester I, gather one or more mixing in first ammonium acrylate ester II, ethyl cellulose, methylcellulose, polyvinylpyrrolidone, the hydroxypropyl emthylcellulose.
4. a kind of diclofenac preparation of sodium according to claim 1 is characterized in that described cohesive enteric material is one or more mixing in polyacrylic resin II, polyacrylic resin III, the Lac.
5. a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation according to claim 1 is characterized in that described outer coating contains plasticizer, and described plasticizer is one or more mixing in triethyl citrate, diethyl phthalate, certain herbaceous plants with big flowers two dibutyl phthalates.
6. a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation according to claim 1 is characterized in that described pellet preparations is prepared into capsule, tablet or granule.
7. a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation according to claim 1; It is characterized in that preparing the prescription of 1000g micropill: diclofenac sodium 510g; Blank starch ball core 400g, Ammonio Methacrylate Copolymer Type A 60g, Lac 10g; Diethyl phthalate 2g, Pulvis Talci 10g.
8. a kind of sodium dichlorophenolate micro-pill pharmaceutical preparation according to claim 1 is characterized in that described micropill is prepared into diclofenac sodium enteric-soluble controlled-release capsule, diclofenac sodium enteric slow release tablet or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910095834A CN101804030B (en) | 2009-02-12 | 2009-02-12 | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910095834A CN101804030B (en) | 2009-02-12 | 2009-02-12 | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101804030A CN101804030A (en) | 2010-08-18 |
| CN101804030B true CN101804030B (en) | 2012-09-05 |
Family
ID=42606093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910095834A Active CN101804030B (en) | 2009-02-12 | 2009-02-12 | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101804030B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579384B (en) * | 2011-01-17 | 2015-09-02 | 杭州赛利药物研究所有限公司 | Allopurinol slow-release micro pill tablet and preparation method thereof |
| CN102266292B (en) * | 2011-07-14 | 2013-03-13 | 浙江金华康恩贝生物制药有限公司 | Matrix diclofenac potassium sustained-release pellet capsules and production process thereof |
| CN105520912A (en) * | 2014-09-28 | 2016-04-27 | 天津尖峰弗兰德医药科技发展有限公司 | Isoginkgetin micro-pills and preparation method thereof |
| CN104510724A (en) * | 2015-01-08 | 2015-04-15 | 广东中盛药物研究院有限公司 | Pellet composition containing diclofenac sodium and preparation method thereof |
| CN107308127A (en) * | 2016-12-27 | 2017-11-03 | 辅仁药业集团熙德隆肿瘤药品有限公司 | C14H10Cl2NNaO2 multi-unit sustained-release pellet tablet |
| CN111728949B (en) * | 2020-07-17 | 2022-10-04 | 广州帝奇医药技术有限公司 | Insoluble medicine oral sustained-release composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1460470A (en) * | 2003-06-06 | 2003-12-10 | 广东药学院 | Dichlofenac sodium slow-releasing preparation and its preparation method |
| CN101181245A (en) * | 2007-12-19 | 2008-05-21 | 北京星昊医药股份有限公司 | Compound diclofenac natrium capsule |
| CN101322695A (en) * | 2008-08-01 | 2008-12-17 | 海南百那医药发展有限公司 | Piclofenac potassium sustained release capsule and preparing technique thereof |
-
2009
- 2009-02-12 CN CN200910095834A patent/CN101804030B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1460470A (en) * | 2003-06-06 | 2003-12-10 | 广东药学院 | Dichlofenac sodium slow-releasing preparation and its preparation method |
| CN101181245A (en) * | 2007-12-19 | 2008-05-21 | 北京星昊医药股份有限公司 | Compound diclofenac natrium capsule |
| CN101322695A (en) * | 2008-08-01 | 2008-12-17 | 海南百那医药发展有限公司 | Piclofenac potassium sustained release capsule and preparing technique thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101804030A (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101804030B (en) | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof | |
| RU2001132861A (en) | New drug | |
| CN103006612B (en) | Lisinopril controlled-release tablet and preparation method thereof | |
| CN102048701A (en) | Pitavastatin calcium enteric sustained-release micropill preparation and preparation method thereof | |
| CN103127026A (en) | Omeprazole enteric capsule and prepared method thereof | |
| CN101167723B (en) | Valsartan dispersible tablet and preparation method thereof | |
| CN101120931A (en) | Bezafibrate sustained-release composition | |
| CN103520130B (en) | Montelukast sodium time-selective controlled-release tablet and preparation method thereof | |
| CN101836963A (en) | Medicinal application preparation for curing hypertension | |
| CN101658507B (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation | |
| CN105816436B (en) | A kind of Pantoprazole enteric-coated micro-pill, Pantoprazole enteric slow-release tablet agent and preparation method thereof | |
| TW201029667A (en) | Novel method for the preparation of granulates of active constituents, and granulates as obtained | |
| CN101849942B (en) | Medicinal composition for treating hypertension | |
| CN101185624A (en) | Novel composing prescription sustained-release preparation for treating high blood pressure and preparation method thereof | |
| CN104856971B (en) | A kind of pulse dual-release preparation and the preparation method and application thereof | |
| CN101756981A (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| CN102309480B (en) | Compound antihypertensive pharmaceutical composition and preparation method thereof | |
| CN102526049A (en) | Compound diclofenac sodium slow-release preparation and preparation method thereof | |
| CN101422453B (en) | Verapamil hydrochloride delayed-release capsule and preparation method thereof | |
| CN101756987A (en) | Compound sustained-release preparation of guaiacol olycerin ether, pseudoephedrine and dextromethorphan | |
| CN101023943A (en) | Myricetin dispersion tablets for treating cardio-cerebral blood vessel diseases | |
| CN104000821B (en) | Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof | |
| CN103127000A (en) | Isosorbide mononitrate chronopharmacological sustained release pellet drug delivery system and its preparation method | |
| CN106466302B (en) | Oral potassium chloride sustained release tablet and preparation method thereof | |
| RU2316328C1 (en) | Method for correction of partial age androgen deficiency (padam) and preparative formulation of testosterone or its pharmacologically acceptable derivatives for its realization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: West Building in Hangzhou City, Zhejiang province 310052 Binjiang District Lake Road 1180 Huaye hi tech Industrial Park Building No. 2 Patentee after: Hangzhou Saili Medicine Inst. Co., Ltd. Patentee after: Hainan Puli Pharmacy stock Co., Ltd Address before: West Building in Hangzhou City, Zhejiang province 310052 Binjiang District Lake Road 1180 Huaye hi tech Industrial Park Building No. 2 Patentee before: Hangzhou Saili Medicine Inst. Co., Ltd. Patentee before: Hainan Pulin Pharmaceutical Co., Ltd. |